Key Players in Cancer B/D-HPP

Key Players

Body Fluids Other Than Plasma: Daniel Chan, Ruedi Aebersold, David Speicher

 

Breast Cancer: Bill HancockGil OmennSteve CarrPeter James

 

Cancer Biomarkers from Different Cancers: Sudhir SrivastavaJacob Kagan

 

Colon Cancer: Ed NiceConnie JimenezMark Baker 

 

Connections Ca-B/D-HPP to C-HPP: Young-Ki Paik, Bill Hancock

  

Lung Cancer: Sam Hanash

 

Ovarian Cancer: Karin RodlandZhen Zhang

 

Pathway Analysis and Cancer Biology: Pier P. Pandolfi 

 

Plasma Atlas, Peptide Atlas, MRM Atlas: Ruedi AebersoldRobert Moritz 

 

Prostate Cancer: Hui Zhang 

 

Proteogenomics of tumors, assay development, public data release and assay portal: 

Henry Rodriguez, Christopher Kinsinger

 

Tissue Targets: Josip Blender 

 

 

 

Key Technologies Involved

 

  • The high-content application of affinity or antibody-based technologies: antibody microarray, protein microarray, nucleic acid-programmable protein array (NAPPA) - Jashua Labaer, Michael Snyder

 

  • The mass spectrometry (MS)-based platforms (MS/MS): selected reaction monitoring (SRM) or targeted data extraction for candidate proteins from SWATH MS data - Ruedi Aebersold, Robert Moritz, Mary Lopez, Ranganathan,  Amanda Paulovich

 

  • Hybrid methods: immuno-MS such as SISCAPA-MRM - Amanda Paulovich, Steve Carr

 

  • Protein modification based assays including phosphoproteins and glycoproteins - Hui Zhang, Ruedi Aebersold, Richard Drake 

 

  • The traditional antibody-based approaches: Western Blots, ELISA, Immunohistochemistry, etc. - Daniel Chan

 

  • Possibly aptamers - Larry Gold 

Locations 

Cells, animal models, patient tissues, body fluids

 

Appropriate NORMAL controls with good inclusion and exclusion data – Akhilesh Pandey, Bernard Kuster    

© 2014 by Center for Biomarker Discovery & Translation